

PROvision of braces for Patients with knee OsteoArthritis (PROP OA): a randomised controlled trial

Submission date 19/07/2018	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 26/07/2018	Overall study status Completed	<input checked="" type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 27/01/2026	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Osteoarthritis of the knee is very common. It causes pain, problems with walking and movement, and can make daily life very difficult. There is no cure for osteoarthritis, but with treatment, symptoms can be improved allowing people to stay active. Wearing a brace could help patients with osteoarthritis of the knee by reducing the load going through the joint and improving its stability. However, there are mixed reports about whether wearing a knee brace does actually help. This study will help to show whether wearing a knee brace provides more relief for people with painful osteoarthritis of the knee than just having best primary care (education, advice and exercise), and whether this is good value for money for the NHS.

Who can participate?

Patients aged 45 years or older with osteoarthritis of the knee. Patients will be identified after they have consulted their GP with knee pain, by screening physiotherapy referrals in NHS services in Staffordshire, Cheshire, Greater Manchester, and Northumbria, and by asking people to volunteer following local radio and other advertising.

What does the study involve?

All participants receive 'best primary care'. This includes an appointment with a physiotherapist who gives them education about knee osteoarthritis and the benefits of exercise, physical activity and weight loss, advice about how to relieve knee pain, and a knee exercise program. They are also given an information booklet. Half of the participants are randomly chosen to also get a knee brace that is checked by the physiotherapist 2 weeks later. The type of brace they get is based on the physiotherapist's assessment and X-ray findings. They are supported to keep wearing the brace for at least 6 months. This includes text message support to help them with use of the brace. Participants are asked about their pain and symptoms after 3, 6, and 12 months to see whether the knee brace was a useful addition to best primary care. Participants are asked for access to their medical records to see if wearing the knee brace has reduced the need for surgery. Some patients are interviewed to find out more about using the knee brace and whether they followed the advice they had from physiotherapists.

What are the possible benefits and risks of participating?

All participants will receive at least best primary care and some participants also receive a knee brace. These treatments are already used in the NHS for the treatment of knee osteoarthritis and are deemed safe. Some participants may experience skin irritation from knee braces and muscle soreness from exercise. Physiotherapists delivering the treatments advise participants about how to manage such symptoms and participants are able to seek healthcare in addition to the care they receive within the study. Some individuals may need a knee X-ray which involves exposure to ionising radiation. The study procedures for taking X-rays follow routine safety procedures used in the NHS.

Where is the study run from?

The study is being run by Keele University working with the University of Manchester and Newcastle University. Treatments are delivered in clinics held within NHS settings in Staffordshire, Cheshire, Manchester and Northumbria.

When is the study starting and how long is it expected to run for?

September 2018 to May 2024

Who is funding the study?

National Institute for Health Research Health Technology Assessment programme (UK)

Who is the main contact?

Prof. George Peat
g.m.peat@keele.ac.uk

Contact information

Type(s)

Public

Contact name

Dr Nicola Halliday

Contact details

Keele Clinical Trials Unit (CTU)
David Weatherall Building
Keele University
Staffordshire
Stoke on Trent
United Kingdom
ST5 5BG
+44 (0)1782 733899
n.halliday@keele.ac.uk

Type(s)

Scientific

Contact name

Prof George Peat

Contact details

Primary Care Centre Versus Arthritis
School of Medicine
Keele University
Keele
United Kingdom
ST5 5BG
+44 (0)1782 733906
g.m.peat@keele.ac.uk

Additional identifiers

Protocol serial number
HTA 16/160/03

Study information

Scientific Title

A multi-centre, primary care, randomised, parallel-group, superiority trial (with internal pilot) to evaluate the effectiveness of bracing in the management of symptomatic knee osteoarthritis: the PROP OA trial

Acronym
PROP OA

Study objectives

To determine the clinical and cost-effectiveness of adding knee brace (matched to patients' clinical and radiographic presentation and with adherence support) to Best Primary Care compared to Best Primary Care (education, advice and exercise) alone, in adults with symptomatic knee osteoarthritis.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Approved 03/06/2019, North West - Preston Research Ethics Committee (no address; +44 (0)207 104 8206; preston.rec@hra.nhs.uk), ref: 19/NW/0183

Study design
Multi-centre, primary care, randomized, parallel-group, superiority interventional trial (with internal pilot). Masking: trial administrator, data entry administrator, trial statistician.

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Knee osteoarthritis (symptomatic)

Interventions

Participants will be randomised (1:1 allocation, random permuted blocks) to receive either Best Primary Care (comparator) or Best Primary Care plus Bracing with Adherence Enhancing Component (intervention) using a web-based randomisation service. Randomisation will be stratified by clinic site, predominant compartmental distribution of knee osteoarthritis and by presence/absence of self-reported knee buckling.

Comparator: Best Primary Care

Participants randomised to receive Best Primary Care will receive a single, face-to-face consultation with a physiotherapist that will include education, self-help advice on pain management and a lower limb exercise program to be completed at home. Participants will also be provided with high quality written material, and a print out of their exercise program to facilitate their exercise practice at home.

Intervention: Best Primary Care plus Bracing with Adherence Enhancing Component

Participants randomised to receive the intervention will receive an initial face-to-face treatment session with a physiotherapist that will include best primary care (as described above) and prescribing of either a patellofemoral, tibiofemoral unloading, or neutral stabilising knee brace according to their pattern of knee osteoarthritis (based on clinical assessment and plain X-ray findings). Braces will be fitted to ensure maximum comfort and dose of brace use will be individually tailored. Participants will be advised to wear the brace on painful weight-bearing activity, with a starting minimum usage of 1 hour on two or more days per week, gradually increased based on tolerance to wearing the brace on all painful weight-bearing activity up to a maximum of 8 hours per day. Individuals will be advised to wear the brace for 6 months, and continue to wear it beyond this time if they find it beneficial.

Two weeks after the initial treatment session participants will return for a follow-up consultation. During this time the physiotherapist will check response to, and fit of the brace.

Treatment sessions will also be used to elicit self-motivational statements -individualised, motivational prompts to encourage adherence to brace use will be sent to participants via SMS text message (weekly for the first 4 weeks, every fortnight for 8 weeks, and then monthly until the end of the intervention period at 6 months).

Intervention Type

Device

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Knee braces

Primary outcome(s)

Knee Injury and Osteoarthritis Outcome Score (KOOS-5) - composite score of patient-reported pain, other symptoms, activities of daily living, function in sport and recreation and knee-related quality of life at 6 months

Key secondary outcome(s)

Current secondary outcome measures as of 05/10/2023:

Secondary outcomes are captured using participant self-report questionnaires at 3, 6 and 12

months post-randomisation:

1. Pain is measured using the Knee injury and Osteoarthritis Outcome Score (KOOS) pain subscale, Numeric Rating Scale of knee pain on activity, measure of Intermittent and Constant Osteoarthritis Pain (ICOAP); Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) [items for which are included within the KOOS]
2. Arthritis self-efficacy is measured using the Arthritis Self-Efficacy Scale (ASES)
3. Function is measured using the Knee injury and Osteoarthritis Outcome Score Activities of Daily Living (KOOS ADL), Function in Sport and Recreation (KOOS Sport/Rec) subscales and WOMAC
4. Physical activity is measured using the International Physical Activity Questionnaire - Elderly (IPAQ-E)
5. Symptoms are captured using the Knee injury and Osteoarthritis Outcome Score (KOOS)
6. Social participation is measured using the Patient-Reported Outcomes Measurement Information System (PROMIS)
8. Patient global rating of change is measured using a Numeric Rating Scale
9. Treatment response is measured using the OMERACT-OARSI responder criteria (this combines data on pain and function from the WOMAC with patient's global assessment of change)
10. Instability (buckling) is measured by self-report questions
11. Treatment acceptability is measured by self-report questions
12. Adverse events are captured through case report forms (CRF), and direct contact between the CTU and the participant, their PROP OA physiotherapist, GP or the Site PI
13. Adherence to brace use is captured in part through SMS text messages (tapering schedule over the first 6 months of follow-up, with a text message also at 12 months)
14. Cost effectiveness is evaluated using EuroQol EQ-5D-5L, Healthcare resource use (NHS /private), out-of-pocket expenses, Time Off Work. Unit costs from standard UK sources will be sought for all health care resource use items. The average wage for each respondent will be identified using UK Standard Occupational Classification coding and annual earnings data for each job type

Previous secondary outcome measures as of 14/05/2021:

Secondary outcomes are captured using participant self-report questionnaires at 3, 6 and 12 months post-randomisation:

1. Pain is measured using the Knee injury and Osteoarthritis Outcome Score (KOOS) pain subscale, Numeric Rating Scale of knee pain on activity, measure of Intermittent and Constant Osteoarthritis Pain (ICOAP); Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) [items for which are included within the KOOS]
2. Anxiety and Depression is measured using the Hospital Anxiety and Depression Scale (HADS)
3. Arthritis self-efficacy is measured using the Arthritis Self-Efficacy Scale (ASES)
4. Function is measured using the Knee injury and Osteoarthritis Outcome Score Activities of Daily Living (KOOS ADL), Function in Sport and Recreation (KOOS Sport/Rec) subscales and WOMAC
5. Physical activity is measured using the International Physical Activity Questionnaire - Elderly (IPAQ-E)
6. Symptoms are captured using the Knee injury and Osteoarthritis Outcome Score (KOOS)
7. Social participation is measured using the Patient-Reported Outcomes Measurement Information System (PROMIS)
8. Quality of life is measured using Knee injury and Osteoarthritis Outcome Score Quality of Life (KOOS QOL) subscale
9. Patient global rating of change is measured using a Numeric Rating Scale
10. Treatment response is measured using the OMERACT-OARSI responder criteria (this

combines data on pain and function from the WOMAC with patient's global assessment of change)

11. Instability (buckling) is measured by self-report questions

12. Treatment credibility is measured by self-report questions

13. Knee pain-related perceptions and expectations are measured by questions from the Brief Illness Perceptions Questionnaire

14. Adverse events are captured through case report forms (CRF), and direct contact between the CTU and the participant, their PROP OA physiotherapist, GP or the Site PI

15. Adherence to brace use is captured in part through SMS text messages (tapering schedule over the first 6 months of follow-up, with a text message also at 12 months)

16. Cost effectiveness is evaluated using EuroQol EQ-5D-5L, Healthcare resource use (NHS /private), out-of-pocket expenses, Time Off Work. Unit costs from standard UK sources will be sought for all health care resource use items. The average wage for each respondent will be identified using UK Standard Occupational Classification coding and annual earnings data for each job type

Previous secondary outcome measures:

Secondary outcomes are captured using participant self-report questionnaires at 3, 6 and 12 months post randomisation:

1. Pain is measured using the Knee injury and Osteoarthritis Outcome Score (KOOS) pain subscale, Numeric Rating Scale of knee pain on activity, measure of Intermittent and Constant Osteoarthritis Pain (ICOAP); Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) [items for which are included within the KOOS]

2. Anxiety and Depression is measured using the Hospital Anxiety and Depression Scale (HADS)

3. Arthritis self-efficacy is measured using the Arthritis Self-Efficacy Scale (ASES)

4. Function is measured using the Knee injury and Osteoarthritis Outcome Score Activities of Daily Living (KOOS ADL), Function in Sport and Recreation (KOOS Sport/Rec) subscales and WOMAC

5. Physical activity is measured using the Physical Activity Scale for the Elderly (PASE)

6. Symptoms are captured using the Knee injury and Osteoarthritis Outcome Score (KOOS)

7. Social participation is measured using the Patient-Reported Outcomes Measurement Information System (PROMIS)

8. Quality of life is measured using Knee injury and Osteoarthritis Outcome Score Quality of Life (KOOS QOL) subscale

9. Patient global rating of change is measured using a Numeric Rating Scale

10. Treatment response is measured using the OMERACT-OARSI responder criteria (this combines data on pain and function from the WOMAC with patient's global assessment of change)

11. Instability (buckling) is measured by self-report questions

12. Treatment credibility is measured by self-report questions

13. Knee pain-related perceptions and expectations are measured by questions from the Brief Illness Perceptions Questionnaire

14. Adverse events are captured in part through SMS text messages (monthly over the first 6 months of follow-up, with a text message also at 12 months) and through case report forms (CRF), and direct contact between the CTU and the participant, their PROP OA physiotherapist, GP or the Site PI

15. Adherence to brace use is captured in part through SMS text messages (monthly over the first 6 months of follow-up, with a text message also at 12 months)

16. Cost effectiveness is evaluated using EuroQol EQ-5D-5L, Healthcare resource use (NHS /private), out-of-pocket expenses, Time Off Work. Unit costs from standard UK sources will be sought for all health care resource use items. The average wage for each respondent will be

identified using UK Standard Occupational Classification coding and annual earnings data for each job type

Completion date

31/05/2024

Eligibility

Key inclusion criteria

Current inclusion criteria as of 14/05/2021:

1. Aged 45 years and over
 2. Residing in England
 3. Clinically significant knee pain on weight bearing (NRS ≥ 4)
 4. With or without knee instability or buckling
 5. Able to have knee x-ray
 6. Able to read and write English
 7. Access to a mobile phone that can receive SMS text messages
 8. Able to give full informed consent
 9. Willing to participate
-

Previous inclusion criteria:

1. Aged 45 years and over
2. Residing in England
3. Clinically significant knee pain on weight bearing (NRS ≥ 4)
4. With or without knee instability or buckling
5. No morning joint-related stiffness or morning stiffness that lasts no longer than 30 minutes
6. Able to have knee x-ray
7. Able to read and write English
8. Access to a mobile phone that can receive SMS text messages
9. Able to give full informed consent
10. Willing to participate

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

45 years

Upper age limit

100 years

Sex

All

Total final enrolment

466

Key exclusion criteria

Current inclusion criteria as of 14/05/2021:

1. Red flags in the history or clinical examination that may indicate further investigation or referral for possible serious underlying pathology
2. Vulnerable individuals (e.g. in palliative phase of care for cancer, unstable mental health disorders)
3. Inflammatory arthritis (e.g. rheumatoid arthritis, psoriatic arthritis)
4. Symptoms not attributable to knee osteoarthritis
5. Previous total knee replacement, high tibial osteotomy, or autologous cartilage implantation
6. On the waiting list for TKR/THR within the next 6 months
7. Unwilling to wear a knee brace
8. Brace size unavailable for leg circumference
9. Knee brace contraindicated (superficial wounds where the knee brace would reside, psoriasis, eczema or poor circulation, arterial insufficiency, or severe varicosities that could result in skin at risk with regular brace wear, a history of thrombophlebitis in either leg)
10. Recent/routine knee brace wear within the last 3 months
11. Nursing home resident
12. Unable to attend clinic
13. Close family member already a trial participant
14. Knee injection in the last 3 months
15. Course of physiotherapy in the last 3 months
16. Significant neurological disorder (e.g. stroke, Parkinson's disease, multiple sclerosis, dementia)
17. Fibromyalgia
18. Autologous cartilage implantation in last 12 months in the knee to be treated
19. Significant fixed flexion deformity that prevents fitting of brace

Previous exclusion criteria:

1. Red flags in the history or clinical examination that may indicate further investigation or referral for possible serious underlying pathology
2. Vulnerable individuals (e.g. in palliative phase of care for cancer, unstable mental health disorders)
3. Inflammatory arthritis (e.g. rheumatoid arthritis, psoriatic arthritis)
4. Symptoms not attributable to knee osteoarthritis
5. Previous total knee replacement, high tibial osteotomy, or autologous cartilage implantation
6. On the waiting list for TKR/THR within the next 6 months
7. Unwilling to wear a knee brace
8. Brace size unavailable for leg circumference
9. Knee brace contraindicated (superficial wounds where the knee brace would reside, psoriasis, eczema or poor circulation, arterial insufficiency, or severe varicosities that could result in skin at risk with regular brace wear, a history of thrombophlebitis in either leg)
10. Recent/routine knee brace wear within the last 3 months
11. Nursing home resident
12. Unable to attend clinic

- 13. Close family member already a trial participant
- 14. Knee injection in the last 3 months
- 15. Course of physiotherapy in the last 3 months

Date of first enrolment

25/11/2019

Date of final enrolment

16/09/2022

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Keele CTU

David Weatherall Building

Keele University

Stoke on Trent

England

ST5 5BG

Sponsor information

Organisation

Keele University

ROR

<https://ror.org/00340yn33>

Funder(s)

Funder type

Government

Funder Name

Health Technology Assessment Programme

Alternative Name(s)

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from James Bailey (medicine.datasharing@keele.ac.uk). The datasets have to be requested on a case-by-case basis although multiple objectives from one dataset can be stated. To access data reasoning has to be provided in the application form along with a study protocol and a short CV for the study CI/PI. Only team members listed in the application form should have access to the data. Consent from the participants would have been obtained, if necessary for the study and any data provided would be anonymised accordingly. Information on how Keele uses information can be found here: <https://www.keele.ac.uk/legalgovernancecompliance/legalandinformationcompliance/informationgovernance/>

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		26/01/2026	27/01/2026	Yes	No
Protocol article		26/03/2021	13/08/2021	Yes	No
Basic results		12/05/2025	20/05/2025	No	No
HRA research summary			20/09/2023	No	No
Protocol file	version v2.1	10/07/2019	15/05/2020	No	No
Protocol file	version 2.4	08/12/2021	16/01/2024	No	No
Statistical Analysis Plan	version 1.0	13/09/2023	15/09/2023	No	No
Statistical Analysis Plan	Data Analysis Plan version 1.1	03/03/2025	25/03/2025	No	No
Study website		11/11/2025	11/11/2025	No	Yes